drugset / Trial / NCT04943445
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Phase 2
Active not recruiting
43 enrolled
Latin American Cooperative Oncology Group
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx who are candidates for organ preservation.
Timeline
- Start
- 2022-02-22
- Primary completion
- 2025-10-16
- Completion
- 2025-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |